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Background: A high early protein intake is associated with rapid postnatal weight gain and altered body composition.
We aimed to evaluate the safety of a low-protein formula in healthy full-term infants.
Methods: A randomized controlled trial was conducted. A total of 118 infants were randomized to receive two different
protein content formulas (formula A or formula B (protein content: 1.2 vs. 1.7 g/100 mL, respectively)) for the first 4 months
of life. Anthropometry and body composition by air displacement plethysmography were assessed at enrolment and at two
and 4 months. The reference group comprised 50 healthy, exclusively breastfed, full-term infants.
Results:Weight gain (g/day) throughout the study was similar between the formula groups (32.5 ± 6.1 vs. 32.8 ± 6.8) and in
the reference group (30.4 ± 5.4). The formula groups showed similar body composition but a different fat-free mass content
from breastfed infants at two and 4 months. However, the formula A group showed a fat-free mass increase more similar
to that of the breastfed infants. The occurrence of gastrointestinal symptoms or adverse events was similar between the
formula groups.
Conclusions: Feeding a low-protein content formula appears to be safe and to promote adequate growth, although
determination of the long-term effect on body composition requires further study.
Trial registration: The present study was retrospectively registered in ClinicalTrials.gov (trial number: NCT03035721 on
January 18, 2017).
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Increasing evidence indicates that early life represents a
critical time window in terms of developmental program-
ming [1]. A strict relationship between early growth
pattern and later health outcomes has been reported,
implicating nutrition as the underlying mechanism [2].
Breastfeeding is recommended as the normative standard
for infants’ nutrition. Breastfed infants are adapted to a rela-
tively high-fat, low-protein diet, which allows adequate
growth without a concurrent increased risk for later adverse* Correspondence: nadia.liotto@policlinico.mi.it; nadia.liotto@gmail.com
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that non-breastfed infants who are fed a high protein for-
mula during the first year of life show rapid weight gain,
which, in turn, has been associated with an increased risk
of overweight and obesity later in life [4, 5].
Growth and body composition development contribute
to the programming process and are affected by early
feeding choices [6]. Compared to breastfed infants, who
achieve a rapid increase in fat mass content within the
first 4–6 months of age, formula-fed infants show a higher
fat-free mass content in the first months of life, with a
tendency towards greater adiposity at the 12th month of
life. These findings suggest that formula feeding is associ-
ated with an alteration in body composition development,
which could partially be due to the high protein intake
consumed by formula-fed infants and could negativelyle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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or long-term appetite regulation [7].
Currently, formulas must meet the permitted protein
amounts, which allow a protein range between 1.8 and
3.0 g/100 kcal [8–10]. However, there is no agreement
on the appropriate amount of protein in infant formulas
[11]. The United States Food and Drug Administration
recommends a protein content ranging between 1.8 and
4.5 g/100 kcal, according to the biological quality of pro-
tein [12]. Recently, the European Food Safety Authority
proposed to lower the maximum protein content of
infant formula to 2.5 g/100 kcal. In addition, it has been
recommended that formulas with a protein content
between 1.80 and 2 g/100 kcal should undergo clinical
assessments of their safety and suitability [7].
In this study, we aimed to evaluate the tolerability and
safety of a formula with a protein content similar to that
of the mature human milk in healthy full-term infants
by investigating effects on growth and gastrointestinal
tolerability and by identifying adverse effects.
Methods
Subjects
All consecutive newborns admitted to the authors’ institu-
tion between June 2014 and January 2016 were screened
for eligibility. Inclusion criteria for all enrolled infants
were as follows: healthy, singleton, full-term infants (ges-
tational age 37/0 to 41/6 weeks), with a birth weight
adequate for gestational age (>10th percentile and <90th
percentile for gestational age) according to the World
Health Organization growth charts (available at http://
www.who.int/childgrowth/standards/en/), and aged up to
3 weeks when entering the study. Exclusion criteria were
the presence of congenital diseases, chromosomal abnor-
malities and/or conditions that could interfere with
growth, such as brain, metabolic, cardiac and gastrointes-
tinal diseases, perinatal infections, being born to a mother
affected by endocrine and/or metabolic diseases, or having
a family history of allergic disease.
Design
We conducted a prospective, controlled, single-blinded ran-
domized trial. All mothers of infants enrolled in the study
were encouraged to breastfeed their infants for at least
4 months. Enrolment and randomization occurred concur-
rently and were performed within 3 weeks after birth. If
mothers could not or intended not to breastfeed their
infants, the study investigators asked the mothers for their
consent to participate in the study. Infants were random-
ized to receive either formula A or formula B. The compos-
ition differences of formula A vs. formula B were in energy
(65 vs. 68 kcal/100 mL), protein (1.2 vs. 1.7 g/100 mL),
protein-to-energy ratio (1.9 vs. 2.5 g/100 kcal), carbohy-
drates (8 vs. 7.1 g/100 mL), fat (3.1 vs. 3.5 g/100 mL). Therandomization was performed by an independent investiga-
tor using a computer-generated randomization list with a
random permuted block size of 4. Infants were fed on
demand. At enrolment, parents were instructed to record
the daily quantities of milk consumed by the infants. Energy
and protein daily intakes were then calculated.
To investigate the safety of formula A without any bias,
a 4-month intervention period was selected during which
the infants were fed only formula.
Anthropometry (weight, length, and head circumference)
and body composition were assessed at enrolment, 2 and
4 months of age. Parents were asked to keep a diary on the
occurrence of gastrointestinal symptoms or any other
symptoms and were contacted every 2 weeks by either
clinic visits or phone calls.
The reference group consisted of a cohort of healthy,
exclusively breastfed, full-term infants.
Procedures
Growth parameters
Anthropometric and body composition measurements
were performed by three medical investigators who were
blinded to the allocated treatment. Body weight, length
and head circumference were measured according to
standard procedures [13]. Weight was measured on an
electronic scale accurate to 0.1 g (PEA POD Infant Body
Composition System; Cosmed, Concord, CA, USA). Body
length was measured to the nearest 1 mm on a Harpenden
neonatometer (Holtain, Crymych, UK). Head circumfer-
ence was measured to the nearest 1 mm using non-stretch
measuring tape. Z-score values for age were calculated
using the z-score calculator provided by the World Health
Organization [WHO Anthro (version 3.2.2, January 2011)].
Weight velocity was calculated as the change in body
weight from the weight at study enrolment divided by the
time interval from enrolment to the assessment at 4 months
[14]. Fat mass and fat-free mass increases (g/day) were also
calculated, respectively, as the change in fat mass and fat-
free mass content from fat mass and fat-free mass content
at study enrolment divided by the time interval from enrol-
ment to the assessments at 2 and 4 months.
Body composition was assessed using an air-displacement
plethysmography (PEA POD Infant Body Composition
System; COSMED, Italy). A detailed description of the PEA
POD’s physical design, operating principles, validation, and
measurement procedures is provided elsewhere [15, 16].
Gastrointestinal tolerance parameters
The occurrence of spitting up, vomiting and colic, defined
as intermittent attacks of abdominal pain when the baby
screamed and drew up his/her legs but that abated be-
tween episodes, was recorded. Colic was further classified
as severe if the episodes occurred more than twice per
day. Daily frequency of stool passage was also recorded.
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Adverse events were assessed based on inquiries to the
parents and on daily records. All adverse events were eval-
uated by the investigator for causal relationship to the
study feeding and for severity. An adverse event was
defined as any event that was not consistent with the
information provided in the consent form or that could
not reasonably be expected to accompany the natural his-
tory and progression of the subject’s condition throughout
the study. Adverse events were considered serious if they
were fatal or life-threatening, required hospitalization or
surgical intervention, resulted in persistent or significant
disability/incapacity or were considered to be medically
relevant by the investigator. All other adverse events were
categorized as non-serious.
Statistical analysis
We hypothesized that the weight gain of the infants fed
the formula A would be similar to that of infants fed the
formula B. Studying 50 infants per group would permit
detection of a difference of 4 g/day ±5.7 standard devi-
ation (95% Confidence Interval: − 1.8; − 6.8), in weight
gain through the study, so that the cumulative growth
difference would not be lower than the standard deviation
for weight (610 g) [17, 18]. Thus, assuming a mean growth
velocity of 25 g/day in the infants fed the formula B, the
growth of the infants fed the formula A would not be
lower than 18.8 g/day or higher than 23.2 g/day.
Breastfeeding group infants were not randomized and
constituted the reference group.
Continuous variables were reported as the mean and
standard deviation (SD). Categorical variables were re-
ported as numbers or percentages. To test the hypoth-
esis that the weight gain of the infants fed the 1.2 g of
protein content formula (formula A) would be similar to
that of infants fed the 1.7 g of protein content formula
(formula B), differences between groups in measure-
ments of growth and body composition parameters were
assessed by analysis of variance. The χ2 test was used for
comparisons between discrete variables. Bonferroni cor-
rections for multiple comparisons were conducted be-
tween the two formula groups and the reference group.
Statistical significance was set at alpha = 0.05. Statistical
analyses were conducted using SPSS (Statistical Package
for the Social Sciences) version 12 software (SPSS Inc.,
Chicago, IL, USA).
Results
Study population
A total of 274 infants were screened between June 2014
and January 2016; 168 infants were enrolled and random-
ized into one of the two study groups or, if fully breastfed,
were included in the breastfeeding group. The mean age
at enrolment was 5.3 ± 3.5 days. During the interventionperiod, 18 infants (11%) dropped out. The trial profile is
shown in Fig. 1. No differences in the characteristics at
birth or in the growth measurements, when last assessed,
were observed between infants who were lost at follow-up
and the infants who were evaluated.
The baseline characteristics of the enrolled infants are
summarized in Table 1. No differences between the two
formula groups and the reference group were found.
Growth and body composition
In Table 2, the anthropometric measurements throughout
the study of enrolled infants are shown. Growth parameters
were similar between the two formula study groups at each
study point. The infants fed formula A and the formula B
showed a slightly different growth pattern throughout the
study compared to the breastfed infants. At 2 months of
life, the infants fed formula A were heavier than the con-
trol group, whereas no differences were found at 4 months
between the formula fed infants and the breastfed infants.
Similar results were found taking into account the z-score
values. The length values were similar among the groups
at each study point, whereas the head circumference was
greater in infants fed formula A and formula B compared
to breastfed infants at 2 months. Regarding z-score
parameters, infants fed formula A showed a higher value
at enrolment compared to the formula B fed infants. Simi-
lar length z-scores were found at two and 4 months for all
infants enrolled.
At fourth months only infants fed formula A showed a
greater head circumference compared to breastfed infants.
The mean weight gain (g/day) throughout the study
was not different between the formula A and formula B
groups [32.8 ± 6.8 (95% CI: 30.9–34.9) vs. 32.5 ± 6.1 (95%
CI: 30.6–34.4), respectively] and from the breastfed
infants [30.4 ± 5.4 (95% CI: 28.7–32.0)].
In Table 3, the body composition parameters are re-
ported. No difference was found between the formula
groups at any study point. Infants of the formula A and
formula B groups showed similar fat mass deposition at
each study points compared to the breastfed infants,
whereas a different fat-free mass content in comparison
to breastfed infants at two and 4 months was detected.
In Table 4, the fat mass and fat-free mass increase (g/day)
during the study period are shown. No difference in fat mass
or fat-free mass increase was found between the formula A
and formula B groups throughout the study. However,
unlike what was observed for the formula B group, the
formula A group showed a mean fat-free mass increase
value similar to that of the breastfed infants, particularly
from enrolment to 2 months.
Nutritional intakes
In Table 5, the nutritional intakes during the intervention
period (2 months and 4 months) for the formula study
Fig. 1 The trial profile
Table 2 Anthropometric measurements at each study point in
enrolled infants
Formula A
group
Formula B
group
Breastfeeding
group
P
Weight (g) Enrolment 3095.3 ± 333 2999.9 ± 428 2971.8 ± 444 ns
2 months 5341.5 ± 623 5174.1 ± 621 4999.2 ± 651 c: 0.033
4 months 6856.5 ± 832 6685.9 ± 800 6480.9 ± 823 ns
Weight
z-score
Enrolment −0.32 ± 0.8 − 0.52 ± 1.1 − 0.69 ± 1.0 ns
2 months −0.08 ± 0.7 − 0.35 ± 0.9 − 0.55 ± 0.9 c: 0.033
4 months 0.12 ± 0.9 −0.18 ± 0.9 −0.35 ± 0.9 c: 0.048
Length (cm) Enrolment 49.7 ± 1.9 49.1 ± 2.0 49.1 ± 2.3 ns
2 months 57.1 ± 2.5 56.8 ± 2.8 57.1 ± 2.4 ns
4 months 63.1 ± 2.2 62.5 ± 2.6 62.8 ± 2.4 ns
Length Enrolment −0.38 ± 0.91 −0.51 ± 1.2 −0.55 ± 1.1 a: 0.018
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higher protein intake throughout the study than the
infants fed formula A. The energy intake of infants fed
formula A was lower at 4 months compare to infants fed
formula B.
Gastrointestinal tolerance
In Table 6, data related to gastrointestinal tolerance
during the treatment period are shown. No differences
in the occurrence of any gastrointestinal symptoms
were detected between the formula study groups. Both
groups showed a similar daily stool frequency at each
study point.
Adverse events
Overall, 12 adverse events occurred in 12 infants. Of these,
3 were categorized as serious. Documented reasons for all
adverse events were mostly illnesses that are common
during the first year of life (for example, bronchiolitis,Table 1 Basic characteristics of the enrolled infants
Formula A
group (n = 50)
Formula B
group (n = 50)
Breastfeeding
group (n = 50)
Gestational age (weeks) 38.6 ± 1.1 38.3 ± 1.0 39.2 ± 1.3
Birth weight (g) 3273.6 ± 381 3137.8 ± 433 3180.6 ± 400
Birth length (cm) 49.6 ± 1.2 49.0 ± 2.1 49.1 ± 2.3
Birth head
circumference (cm)
34.2 ± 1.1 33.9 ± 1.3 34.1 ± 1.1
Days at enrolment (n) 5.14 ± 2.2 5.1 ± 3.6 5.3 ± 2.3
Males (n, %) 22 (44) 29 (58) 21 (42)
Caesarean section (n, %) 35 (70) 28 (56) 18 (36)
z-score
2 months −0.26 ± 1.1 −0.61 ± 1.2 − 0.32 ± 1.1 ns
4 months 0.08 ± 0.9 −0.31 ± 1.1 −0.14 ± 0.9 ns
Head
circumference
(cm)
Enrolment 34.2 ± 1.1 33.9 ± 1.3 34.1 ± 1.1 ns
2 months 39.1 ± 1.4 39.0 ± 1.6 38.2 ± 1.3 b: 0.016
c: 0.009
4 months 41.5 ± 1.5 41.7 ± 1.6 40.8 ± 1.4 b: 0.01
Head
circumference
z-score
Enrolment −0.35 ± 0.8 −0.65 ± 1.0 −0.35 ± 0.9 ns
2 months 0.24 ± 1.0 0.20 ± 1.2 −0.38 ± 0.9 b: 0.034
c: 0.017
4 months 0.50 ± 1.1 0.39 ± 1.0 −0.24 ± 1.0 b: 0.020
c: 0.020
a: formula B group vs. formula A group
b: formula B group vs. breastfeeding group
c: formula A group vs. breastfeeding group
Table 3 Body composition parameters of the enrolled infants
Formula A
group
Formula B
group
Breastfeeding
group
P
Fat mass (g) Enrolment 251.0 ± 132 258.1 ± 127 202.1 ± 119 ns
2 months 1185.0 ± 274 1122.8 ± 273 1137.1 ± 320 ns
4 months 1778.4 ± 454 1674.3 ± 357 1772.7 ± 413 ns
Fat mass (%) Enrolment 7.7 ± 3.6 8.2 ± 3.5 6.5 ± 3.2 ns
2 months 21.2 ± 3.8 21.3 ± 3.8 22.6 ± 4.1 ns
4 months 25.9 ± 4.0 25.2 ± 4.3 27.5 ± 4.3 ns
Fat-free
mass (g)
Enrolment 2844.3 ± 284 2798.4 ± 357 2765.9 ± 375 ns
2 months 4177.2 ± 422 4105.6 ± 423 3825.0 ± 414 b: 0.01
c: < 0.001
4 months 5014.8 ± 514 4952.0 ± 493 4565.4 ± 428 b: 0.002
c: < 0.001
Fat-free
mass (%)
Enrolment 92.0 ± 3.8 91.7 ± 3.7 93.4 ± 3.2 ns
2 months 78.1 ± 3.2 78.7 ± 3.8 77.4 ± 4.1 ns
4 months 74.1 ± 4.0 74.8 ± 4.3 72.2 ± 4.6 b: 0.033
a: formula B group vs. formula A group
b: formula B group vs. breastfeeding group
c: formula A group vs. breastfeeding group
Table 5 Nutritional intakes during the intervention period
(2 months and 4 months of life) in the two formula study groups
Formula A
group
Formula B
group
p
2 months Numbers of
feedings/day
5.3 ± 0.7 5.2 ± 0.8 0.408
Volume of milk
(ml/kg/day)
156.5 ± 25.1 153.0 ± 21.6 0.498
Energy (kcal/kg/day) 101.7 ± 16.3 104.0 ± 14.7 0.507
Proteins (g/kg/day) 1.88 ± 0.3 2.60 ± 0.36 < 0.0001
4 months Numbers of
feedings/day
4.7 ± 0.7 4.6 ± 0.6 0.664
Volume of milk
(ml/kg/day)
130.3 ± 16.5 135.6 ± 20.5 0.188
Energy (kcal/kg/day) 84.7 ± 10.7 92.25 ± 13.9 0.006
Proteins (g/kg/day) 1.56 ± 1.9 2.31 ± 0.35 < 0.0001
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There were no differences in the occurrence of adverse
events during the study between the two study groups.
Discussion
The results of the current study indicate that feeding for-
mula A (1.9 g/100 kcal) is well tolerated and safe, allowing
adequate growth, as demonstrated by the achievement of
z-score values of anthropometric parameters close to the
median of the reference values [19]. However, it must be
noted that although it is adequate, the growth supported
by the consumption of formula A appears to be associated
with a preferential deposition of fat-free mass rather than
fat mass through the study period. Therefore, considering
the different pattern of growth that formula fed infants
showed compared to that observed in breastfed infants,
being formula fed, also with a lower protein content, doesTable 4 Mean fat mass and fat-free mass increase (g/day) during
the study period
Formula
A group
Formula
B group
Breastfeeding
group
P
Fat mass
increase
(g/day)
Enrolment-
2 months
17.2 ± 5.6 16.5 ± 5.5 17.1 ± 5.0 ns
2–4 months 11.5 ± 6.5 10.7 ± 5.5 12.4 ± 8.2 ns
Enrolment-
4 months
13.3 ± 4.1 12.7 ± 3.1 13.7 ± 3.4 ns
Fat-free
mass
increase
(g/day)
Enrolment-
2 months
24.6 ± 5.5 29.3 ± 15.3 21.1 ± 7.2 b: 0.001
2–4 months 14.0 ± 6.5 14.3 ± 5.6 13.9 ± 9.3 ns
Enrolment-
4 months
19.0 ± 3.6 21.5 ± 8.0 16.5 ± 4.5 b: 0.001
a: formula B group vs. formula A group
b: formula B group vs. breastfeeding group
c: formula A group vs. breastfeeding groupnot apparently prevent the potential alteration in body
composition development described in formula-fed
infants [7]. It could be assumed that the major amount of
fat-free mass of formula fed infants could be explained by
formula’s macronutrients content. Kashyap et al. [20], in a
study conduct on premature infants, demonstrated that
there was a significant positive correlation between the
protein storage and carbohydrate intake that was not
related to fat intake. In the present study, we did not ana-
lyse the macronutrient content of human milk of the
reference group. It has been demonstrated that the human
milk mean carbohydrate and fat content in the first
8 weeks postpartum is 6.2 ± 0.9 g/dL and 4.1 ± 0.7 g/dL
respectively [21]. Therefore, the major amount of fat-free
mass observed in formula fed infants compared to refer-
ence group could be explained by the higher carbohydrate
intake, which could facilitate the protein storage. Con-
versely, it could also be speculated that the lack of an
effect on modulating the development of body compos-
ition in the first months of life between the two formula
groups could be partially explained by the relatively lim-
ited duration of the intervention. When considering the
fat-free mass increase through the study, the infants in the
formula A group showed a mean fat-free mass increase
similar to that of breastfed infants, particularly between en-
rolment and 2 months. Furthermore, the lack of differenceTable 6 Gastrointestinal tolerance in the enrolled infants in the
two study groups during the study
Spitting
n (%)
Vomiting
n (%)
Colic
n (%)
Daily stool
frequency
mean (SD)
2 months Formula A group 30 (60) 1 (2) 27 (54) 1.6 ± 1.0
Formula B group 25 (50) 4 (8) 25 (50) 1.5 ± 0.7
4 months Formula A group 22 (44) 0 (0) 8 (16) 1.4 ± 0.7
Formula B group 30 (60) 0 (0) 10 (20) 1.6 ± 0.7
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formula groups at the end of the study could be because
the study was actually powered on weight gain rather than
fat-free mass increase.
The results of the present study concerning the safety of
the consumption of a low-protein formula in healthy term
infants are consistent with previously published data.
Abrams et al. [22] conducted a systematic review, including
6 studies, and concluded that feeding a low-protein formula
leads to adequate growth during infancy and early child-
hood. Patro-Gołąb et al. [11] investigated the evidence avail-
able in the literature related to the effects of different
protein formula contents (range 1.1–3.2 g/100 mL) on
infants’ growth. The authors reported that the studies
included in their systematic review evaluated only the short-
term effects on growth, from three to 5 months of age, with-
out finding any modification of infants’ growth with regard
to length and weight gains and BMI, regardless of protein
formula concentration.
To our knowledge, there is a paucity of studies investigat-
ing the safety of feeding a low-protein formula, including
body composition assessment. The CHOP study demon-
strated that the consumption of a formula with a protein
ratio of 1.77 g/100 kcal during the first year of life promotes
ponderal growth similar to that of breastfed infants and
lower than that of infants fed a formula with a high protein-
energy intake (2.9 g/100 kcal) and is associated with a lower
risk for being obese at school age [4, 5]. In agreement with
our results, the authors did not find any significant differ-
ence in the fat mass or fat-free mass content at 6 months of
age [23]. However, the authors reported that a higher pro-
tein intake in formula-fed infants appears to promote
visceral fat mass accumulation at prepubertal age, which is a
known risk factor for adverse metabolic and health conse-
quences, whereas the deposition of subcutaneous fat appears
not to be affected [24]. It could be then hypothesized that
although no significant difference was detected in the total
fat-free mass content between the formula study groups in
the present study, the consumption of a low protein intake
in this critical time window could contribute to the develop-
mental programming of fat mass distribution in later life.
The main strength of this work is represented by the fact
that this study is a prospective, longitudinal study, con-
ducted on a relatively large number of infants. However, it
must be taken into consideration that both the intervention
and the follow-up period were relatively short; as a result,
the potential cumulative effect of consuming a low-protein
formula in early infancy on growth and body composition
in the medium to long term has not been assessed.
Conclusion
On the basis of the present findings, the consumption of a
low-protein formula during the first months of life appears
to be safe and to allow adequate growth. Additional studiesand a longer follow-up are needed to gain further insight
into the effect that different protein formula contents have
on body composition development.
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